Pune, India

B Shivdavkar Radhakrishna

This inventor holds 1 USPTO granted patent. Top assignee: Lupin, Inc.. Active years: 2020.


% Patents Active = 100.0

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
1 patent (USPTO):Explore Patents

Title: B Shivdavkar Radhakrishna: Innovator in Pharmaceutical Chemistry

Introduction

B Shivdavkar Radhakrishna is a notable inventor based in Pune, India. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of processes for drug formulation. His work is characterized by a focus on improving the stability and purity of pharmaceutical compounds.

Latest Patents

Radhakrishna holds a patent for the "Process for the preparation of pure and stable crystalline Raltegravir potassium Form 3." This invention provides improved, commercially viable, and consistently reproducible processes for the preparation of pure and stable crystalline Raltegravir potassium Form 3 and its pharmaceutical composition. This innovation is crucial for enhancing the efficacy and safety of the drug.

Career Highlights

He is currently associated with Lupin, Inc., a leading global pharmaceutical company. His role involves research and development, where he applies his expertise to create innovative solutions in drug formulation. Radhakrishna's work has contributed to the advancement of pharmaceutical sciences and has the potential to impact patient care positively.

Collaborations

Some of his notable coworkers include Purna Chandra Ray and Samir Shanteshwar Shabade. Their collaborative efforts in research and development have further strengthened the innovative capabilities of their team.

Conclusion

B Shivdavkar Radhakrishna is a prominent figure in pharmaceutical innovation, with a focus on enhancing drug stability and purity. His contributions through patents and collaboration with esteemed colleagues underscore his commitment to advancing healthcare solutions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…